Trade Agios Pharmaceuticals, Inc. - AGIO CFD
Add to favourite- Summary
- Historical Data
| Spread | 0.35 | ||||||||
|
Long position overnight fee
Long position overnight funding adjustment
Go to platform | -0.026235% | ||||||||
|
Short position overnight fee
Short position overnight funding adjustment
Go to platform | 0.004012% | ||||||||
| Overnight fee time | 21:00 (UTC) | ||||||||
| Min traded quantity | 1 | ||||||||
| Currency | USD | ||||||||
| Margin | 5.00% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
| Prev. Close | 44.25 |
| Open | 44.1 |
| 1-Year Change | 64.92% |
| Day's Range | 43.76 - 45.26 |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Sep 11, 2024 | 44.25 | 1.15 | 2.67% | 43.10 | 44.44 | 42.68 |
| Sep 10, 2024 | 44.25 | 0.87 | 2.01% | 43.38 | 44.59 | 43.38 |
| Sep 9, 2024 | 43.86 | 1.09 | 2.55% | 42.77 | 44.06 | 42.68 |
| Sep 6, 2024 | 43.22 | -0.23 | -0.53% | 43.45 | 44.31 | 42.76 |
| Sep 5, 2024 | 43.72 | 0.31 | 0.71% | 43.41 | 44.14 | 43.22 |
| Sep 4, 2024 | 44.69 | 0.60 | 1.36% | 44.09 | 44.84 | 43.38 |
| Sep 3, 2024 | 44.48 | 0.52 | 1.18% | 43.96 | 46.56 | 43.96 |
| Aug 30, 2024 | 45.84 | 1.31 | 2.94% | 44.53 | 46.08 | 44.53 |
| Aug 29, 2024 | 45.79 | 1.16 | 2.60% | 44.63 | 46.67 | 44.63 |
| Aug 28, 2024 | 45.09 | -1.51 | -3.24% | 46.60 | 48.88 | 43.19 |
| Aug 27, 2024 | 46.91 | 0.54 | 1.16% | 46.37 | 47.12 | 45.65 |
| Aug 26, 2024 | 46.51 | 0.65 | 1.42% | 45.86 | 46.87 | 45.84 |
| Aug 23, 2024 | 45.90 | 0.11 | 0.24% | 45.79 | 46.51 | 45.33 |
| Aug 22, 2024 | 45.63 | -0.79 | -1.70% | 46.42 | 46.58 | 44.78 |
| Aug 21, 2024 | 46.98 | 2.28 | 5.10% | 44.70 | 47.43 | 43.96 |
| Aug 20, 2024 | 44.73 | -0.32 | -0.71% | 45.05 | 45.54 | 44.53 |
| Aug 19, 2024 | 45.39 | 0.60 | 1.34% | 44.79 | 45.51 | 44.29 |
| Aug 16, 2024 | 44.99 | 1.28 | 2.93% | 43.71 | 45.35 | 43.70 |
| Aug 15, 2024 | 44.85 | 0.14 | 0.31% | 44.71 | 45.65 | 44.45 |
| Aug 14, 2024 | 44.35 | 0.33 | 0.75% | 44.02 | 44.97 | 43.71 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 20
- 100
- 500
- 1000
- 10000
Agios Pharmaceuticals, Inc. Company profile
About Agios Pharmaceuticals Inc
Agios Pharmaceuticals, Inc. is a biopharmaceutical company. The Company's lead product candidate in its genetically defined disease (GDD) portfolio, PYRUKYND (Mitapivat), is an activator of both wild-type and a variety of mutant pyruvate kinase (PK) enzymes, for the treatment of hemolytic anemias. The Mitapivat is an orally available small molecule and a potent activator of the pyruvate kinase R (PKR) enzymes. In addition, it is also evaluating mitapivat for the treatment of a- and b-thalassemia and sickle cell disease (SCD) in ongoing clinical trials. The Company is also developing AG-946, a clinical-stage oral activator of PKR enzymes for the treatment of hemolytic anemias and other indications, including SCD and anemia associated with low-to intermediate-risk myelodysplastic syndrome (L-IR MDS), which is in Phase I clinical study.
Financial summary
BRIEF: For the fiscal year ended 31 December 2021, Agios Pharmaceuticals Inc revenues was not reported. Net loss before extraordinary items increased 8% to $356.5M. Higher net loss reflects Research and development increase of 20% to $232.4M (expense), General and administrative increase of 15% to $92.5M (expense), Interest Income decrease of 87% to $836K (income). Basic Earnings per Share excluding Extraordinary Items decreased from -$4.77 to -$5.90.
Equity composition
Common Stock $.001 Par, Shares auth and O/s after the offering: 78.3 M auth., 29,380,399 issd. Insider Owns approx.38.04%.(After the IPO) IPO:TBA.
| Industry: | Bio Therapeutic Drugs |
88 Sidney Street
CAMBRIDGE
MASSACHUSETTS 02139
US
News
ECB Preview: cuts expected but the pace is uncertain
Markets expect the ECB to cut rates again in September, but how many more?
12:34, 11 September 2024
Market analysis: US CPI and PPI
Overview of upcoming US inflation data for August, with expectations for a year-over-year CPI drop to 2.6% and core CPI holding steady at 3.2%. Markets will also focus on U.S. PPI data, which is forecasted to show mild growth, reinforcing potential easing inflationary pressures.
07:56, 10 September 2024
Introducing Newsquawk: your new in-platform newsfeed
We are very excited to announce the launch of Newsquawk in the Capital.com platform and app. This new newsfeed is designed to help you get ahead with real-time headlines, personalised stories and in-depth reports – all available directly in the platform and app, where you need them.
14:09, 20 August 2024
Jackson Hole Preview: All eyes on Powell and Gold
The key focus this week will be on Jerome Powell and any insight he may give into the future of monetary policy.
15:24, 19 August 2024
All eyes on inflation: US and UK CPI take centre stage
Just over a month has gone by since the latest CPI data was released in the US and so much has happened since.
14:41, 13 August 2024
European stocks face resistance in their attempt to recover
European stocks struggle to recover as the tech sector faces continued downside pressure in Asia.
13:56, 9 August 2024
Global selloff continues on US economy fears
Thursday’s rise in jobless claims led to a market meltdown in the US stock market as investors became concerned that the Federal Reserve made the wrong decision by keeping rates unchanged on Wednesday.
14:40, 5 August 2024People also watch
Still looking for a broker you can trust?
Join the 640,000+ traders worldwide that chose to trade with Capital.com